Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Vera A. Bittner,Michael Szarek,Philip E. Aylward,Deepak L. Bhatt,Rafael Diaz,Jay M. Edelberg,Zlatko Fras,Shaun G. Goodman,Sigrun Halvorsen,Corinne Hanotin,Robert A. Harrington,J. Wouter Jukema,Virginie Loizeau,Patrick M. Moriarty,Angele Moryusef,Robert Pordy,Matthew T. Roe,Peter Sinnaeve,Sotirios Tsimikas,Robert Vogel,Harvey D. White,Doron Zahger,Andreas M. Zeiher,Gabriel Steg,Gregory G. Schwartz,Heinz Drexel,Mirza Dilic,Renato D. Lopes,Nina N. Gotcheva,Juan-Carlos Prieto,Huo Yong,Patricio Lopez-Jaramillo,Ivan Pecin,Zeljko Reiner,Petr Ostadal,Steen Hvitfeldt Poulsen,Margus Viigimaa,Markku S. Nieminen,Nicolas Danchin,Vakhtang Chumburidze,Nikolaus Marx,Evangelos Liberopoulos,Pablo Carlos Montenegro Valdovinos,Hung-Fat Tse,Robert Gabor Kiss,Denis Xavier,Marco Valgimigli,Takeshi Kimura,Hyo Soo Kim,Sang-Hyun Kim,Andrejs Erglis,Aleksandras Laucevicius,Sasko Kedev,Khalid Yusoff,Gabriel Arturo Ramos Lopez,Marco Alings,Roger M. Correa Flores,Rody G. Sy,Andrzej Budaj,Joao Morais,Maria Dorobantu,Yuri Karpov,Arsen D. Ristic,Terrance Chua,Jan Murin,Anthony J. Dalby,Jose Tunon,H. Asita de Silva,Emil Hagstrom,Christian Muller,Chern-En Chiang,Piyamitr Sritara,Sema Guneri,Alexander Parkhomenko,Kausik K. Ray,Bernard Chaitman,Sheryl F. Kelsey,Anders G. Olsson,Jean-Lucien Rouleau,Maarten L. Simoons,Karen Alexander,Chiara Meloni,Robert Rosenson,Eric J. G. Sijbrands,John H. Alexander,Luciana Armaganijan,Akshay Bagai,Maria Cecilia Bahit,J. Matthew Brennan,Shaun Clifton,Adam D. DeVore,Shalonda Deloatch,Sheila Dickey,Keith Dombrowski,Gregory Ducrocq,Zubin Eapen,Patricia Endsley,Arleen Eppinger,Connie Ng Hess,Mark A. Hlatky,Joseph Dedrick Jordan,Joshua W. Knowles,Bradley J. Kolls,David F. Kong,Sergio Leonardi,Linda Lillis,David J. Maron,Jill Marcus,Robin Mathews,Rajendra H. Mehta,Robert J. Mentz,Humberto Graner Moreira,Chetan B. Patel,Sabrina Bernardez Pereira,Lynn Perkins,Thomas J. Povsic,Etienne Puymirat,William Schuyler Jones,Bimal R. Shah,Matthew W. Sherwood,Kenya Stringfellow,Darin Sujjavanich,Mustafa Toma,Charlene Trotter,Sean F. P. van Diepen,Matthew D. Wilson,Andrew Tze-Kay Yan,Lilia B. Schiavi,Marcelo Garrido,Andres F. Alvarisqueta,Sonia A. Sassone,Anselmo P. Bordonava,Alberto E. Alves De Lima,Jorge M. Schmidberg,Ernesto A. Duronto,Orlando C. Caruso,Leonardo P. Novaretto,Miguel Angel Hominal,Oscar R. Montana,Alberto Caccavo,Oscar A. Gomez Vilamajo,Alberto J. Lorenzatti,Luis R. Cartasegna,Gustavo A. Paterlini,Ignacio J. Mackinnon,Guillermo D. Caime,Marcos Amuchastegui,Oscar R. Codutti,Horacio O. Jure,Julio O. E. Bono,Adrian D. Hrabar,Julio A. Vallejos,Rodolfo A. Ahuad Guerrero,Federico Novoa,Cristian A. Patocchi,Cesar J. Zaidman,Maria E. Giuliano,Ricardo D. Dran,Marisa L. Vico,Gabriela S. Carnero,Pablo N. Guzman,Juan C. Medrano Allende,Daniela F. Garcia Brasca,Miguel H. Bustamante Labarta,Sebastian Nani,Eduardo D. S. Blumberg,Hugo R. Colombo,Alberto Liberman,Hector L. Luciardi,Gabriel D. Waisman,Mario A. Berli,Ruben O. Garcia Duran,Horacio G. Cestari,Hugo A. Luquez,Jorge A. Giordano,Silvia S. Saavedra,Jonathon H. Waites,Nicholas Collins,Allan Soward,Chris L. S. Hii,James Shaw,Margaret A. Arstall,John Horowitz,James F. Rogers,David Colquhoun,Romulo E. Oqueli Flores,Philip Roberts-Thomson,Owen Raffel,Sam J. Lehman,Steven G. M. Coverdale,Paul J. Garrahy,Gregory Starmer,Mark Sader,Patrick A. Carroll,Robert Zweiker,Uta Hoppe,Kurt Huber,Rudolf Berger,Franz Weidinger,Dirk Faes,Kurt Hermans,Bruno Pirenne,Attilio Leone,Etienne Hoffer,Mathias C. M. Vrolix,Luc De Wolf,Bart Wollaert,Marc Castadot,Karl Dujardin,Christophe Beauloye,Geert Vervoort,Harry Striekwold,Carl Convens,John Roosen,Emanuele Barbato,Marc Claeys,Frank Cools,Ibrahim Terzic,Fahir Barakovic,Zlatko Midzic,Belma Pojskic,Emir Fazlibegovic,Azra Durak-Nalbantic,Dusko Vulic,Adis Muslibegovic,Gilmar Reis,Luciano Sousa,Jose C. Nicolau,Flavio E. Giorgeto,Ricardo P. Silva,Lilia Nigro Maia,Rafael Rech,Paulo R. F. Rossi,Maria Jose A. G. Cerqueira,Norberto Duda,Renato Kalil,Adrian Kormann,Jose Antonio M. Abrantes,Pedro Pimentel Filho,Ana Priscila Soggia,Mayler O. N. de Santos,Fernando Neuenschwander,Luiz C. Bodanese,Yorghos L. Michalaros,Freddy G. Eliaschewitz,Maria H. Vidotti,Paulo E. Leaes,Roberto V. Botelho,Sergio Kaiser,Euler Roberto F. Fernandes Manenti,Dalton B. Precoma,Jose C. Moura Jorge,Pedro G. M. de B. Silva,Jose A. Silveira,Wladimir Saporito,Jose A. Marin Neto,Gilson S. Feitosa,Luiz Eduardo F. Ritt,Juliana A. de Souza,Fernando Costa,Weimar K. S. B. Souza,Helder J. L. Reis,Leandro Machado,Jose Carlos Aidar Ayoub,Georgi V. Todorov,Fedya P. Nikolov,Elena S. Velcheva,Maria L. Tzekova,Haralambi O. Benov,Stanislav L. Petranov,Haralin S. Tumbev,Nina S. Shehova-Yankova,Dimitar T. Markov,Dimitar H. Raev,Mihail N. Mollov,Kostadin N. Kichukov,Katya A. Ilieva-Pandeva,Raya Ivanova,Valentina M. Mincheva,Petar V. Lazov,Bojidar I. Dimov,Manohara Senaratne,James Stone,Jan Kornder,Stephen Pearce,Danielle Dion,Daniel Savard,Yves Pesant,Amritanshu Pandey,Simon Robinson,Gilbert Gosselin,Saul Vizel,Gordon Hoag,Ronald Bourgeois,Anne Morisset,Eric Sabbah,Bruce Sussex,Simon Kouz,Paul MacDonald,Ariel Diaz,Nicolas Michaud,David Fell,Raymond Leung,Tycho Vuurmans,Christopher Lai,Frank Nigro,Richard Davies,Gustavo Nogareda,Ram Vijayaraghavan,John Ducas,Serge Lepage,Shamir Mehta,James Cha,Robert Dupuis,Peter Fong,Josep Rodes-Cabau,Hussein Fadlallah,David Cleveland,Thao Huynh,Iqbal Bata,Adnan Hameed,Cristian Pincetti,Sergio Potthoff,Monica Acevedo,Arnoldo Aguirre,Margarita Vejar,Mario Yanez,Guillermo Araneda,Mauricio Fernandez,Luis Perez,Paola Varleta,Fernando Florenzano,Laura Huidobro,Carlos A. Raffo,Claudia Olivares,Jiyan Chen,Yugang Dong,Weijian Huang,Jianzhong Wang,Shi'An Huang,Zhuhua Yao,Lan Cui,Wenhua Lin,Yuemin Sun,Jingfeng Wang,Jianping Li,Xuelian Zhang,Hong Zhu,Dandan Chen,Lan Huang,Shaohong Dong,Guohai Su,Biao Xu,Xi Su,Xiaoshu Cheng,Jinxiu Lin,Wenxia Zong,Huanming Li,Yi Feng,Dingli Xu,Xinchun Yang,Yuannan Ke,Xuefeng Lin,Zheng Zhang,Zeqi Zheng,Zhurong Luo,Yundai Chen,Chunhua Ding,Yang Zheng,Xiaodong Li,Daoquan Peng,Ying Li,Meng Wei,Shaowen Liu,Yihua Yu,Baiming Qu,Weihong Jiang,Yujie Zhou,Xingsheng Zhao,Zuyi Yuan,Ying Guo,Xiping Xu,Xubo Shi,Junbo Ge,Guosheng Fu,Feng Bai,Weiyi Fang,Xiling Shou,Xiangjun Yang,Jian'An Wang,Nicolas Jaramillo,Gregorio Sanchez Vallejo,Diana C. Luna Botia,Rodrigo Botero Lopez,Dora I. Molina De Salazar,Alberto J. Cadena Bonfanti,Juan Diego Higuera,Sandra I. Barrera Silva,Henry J. Garcia Lozada,Julian A. Coronel Arroyo,Jose L. Accini Mendoza,Ricardo L. Fernandez Ruiz,Angela M. Fernandez,Fernando G. Manzur Jatin,Aristides Sotomayor Herazo,Jeffrey Castellanos Parada,Miguel A. Urina Triana,Jindrich Spinar,David Horak,Josef Stasek,David Alan,Vilma Machova,Ales Linhart,Vojtech Novotny,Vladimir Kaucak,Richard Rokyta,Robert Naplava,Zdenek Coufal,Vera Adamkova,Ivo Podpera,Jiri Zizka,Zuzana Motovska,Ivana Marusincova,Premysl Svab,Petr Heinc,Jiri Kuchar,Petr Povolny,Bent Raungaard,Peter Clemmensen,Lia E. Bang,Ole May,Morten Bottcher,Jens D. Hove,Lars Frost,Gunnar Gislason,John Larsen,Peter Betton Johansen,Flemming Hald,Jorgen Jeppesen,Tonny Nielsen,Kjeld S. Kristensen,Piotr Maria Walichiewicz,Jens D. Lomholdt,Ib C. Klausen,Peter Kaiser Nielsen,Flemming Davidsen,Lars Videbaek,Mai Soots,Veiko Vahula,Anu Hedman,sllar Soopold,Kaja Martsin,Marja-Riitta Taskinen,Kimmo Porthan,Juhani K. Airaksinen,Markus Juonala,Tuomas Kiviniemi,Saila Vikman,Pirjo Posio,Jyrki Taurio,Heikki Huikuri,Kari Kaikkonen,Pierre Coste,Emile Ferrari,Olivier Morel,Gilles Montalescot,Gilles Barone-Rochette,Jacques Mansourati,Yves Cottin,Philippe Gabriel Steg,Florence Leclercq,Abdelkader Belhassane,Nicolas Delarche,Franck Boccara,Franck Paganelli,Jerome Clerc,Francois Schiele,Victor Aboyans,Vincent Probst,Jacques Berland,Thierry Lefevre,Irakli Khintibidze,Tamaz Shaburishvili,Zurab Pagava,Ramaz Ghlonti,Zaza Lominadze,George Khabeishvili,Rayyan Hemetsberger,Ursula Rauch-Kroehnert,Matthias Stratmann,Karl-Friedrich Appel,Ekkehard Schmidt,Heyder Omran,Christoph Stellbrink,Thomas Dorsel,Emmanouil Lianopoulos,Roger Marx,Andreas Zirlik,Detlev Schellenberg,Thomas Heitzer,Ulrich Laufs,Stephan Gielen,Bernhard Winkelmann,Steffen Behrens,Karsten Sydow,Gregor Simonis,Thomas Muenzel,Nikos Werner,Stefan Leggewie,Dirk Boecker,Ruediger Braun-Dullaeus,Nicole Toursarkissian,Michael Jeserich,Matthias Weissbrodt,Tim Schaeufele,Joachim Weil,Heinz Voeller,Johannes Waltenberger,Mohammed Natour,Stephan Steiner,Lothar Heidenreich,Uwe Gremmler,Holger Killat,Sotiris Patsilinakos,Athanasios Kartalis,Athanassios Manolis,Dimitrios Sionis,Ioannis Skoumas,Vasilios Athyros,P. I. Frangkiskos Parthenakis,P. I. Georgios Hahalis,John Lekakis,Apostolos Xatzitolios,Sergio R. Fausto Ovando,Juan L. Arango Benecke,Edgar R. Rodriguez De Leon,Bryan P. Y. Yan,David C. W. Siu,Tibor Turi,Bela Merkely,Imre Ungi,Geza Lupkovics,Lajos Nagy,Andras Katona,Istvan Edes,Gabor Muller,Ivan Horvath,Tibor Kapin,Jozsef Falukozy,Mukund Kumbla,Manjinder Sandhu,Sharath Annam,Naveen Reddy Proddutur,Rajendra K. Premchand,Ajaykumar Mahajan,Atul D. Abhyanakar,Prafulla Kerkar,Ravishankar A. Govinda,Abraham Oomman,Dhurjati Sinha,Sachin N. Patil,Dhiman Kahali,Jitendra Sawhney,Abhijeet B. Joshi,Sanjeev Chaudhary,Pankaj Harkut,Santanu Guha,Sanjay Porwal,Srimannarayana Jujjuru,Ramesh B. Pothineni,Minguel R. Monteiro,Aziz Khan,Shamanna S. Iyengar,Jasprakash Singh Grewal,Manoj Chopda,Mahesh C. Fulwani,Aparna Patange,Vijay K. Chopra,Naresh K. Goyal,Rituparna Shinde,Gajendra V. Manakshe,Nitin Patki,Sumeet Sethi,Vengatesh Munusamy,Sunil Karna,Srilakshmi Adhyapak,Ulhas Pandurangi,Rishabh Mathur,Suhas Kalashetti,Ajit Bhagwat,Bagirath Raghuraman,Shiv Kumar Yerra,Prasant Bhansali,Rohidas Borse,Srihari Das,Jabir Abdullakutty,Shireesh Saathe,Priya Palimkar,Shaul Atar,Michael Shechter,Morris Mosseri,Yaron Arbel,Chaim Lotan,Uri Rosenschein,Amos Katz,Yaakov Henkin,Adi Francis,Marc Klutstein,Eugenia Nikolsky,Yoav Turgeman,Majdi Halabi,Ran Kornowski,Michael Jonas,Offer Amir,Yoseph Rozenman,Shmuel Fuchs,Osamah Hussein,Dov Gavish,Zvi Vered,Yoseph Caraco,Mazen Elias,Naveh Tov,Giancarlo Piovaccari,Annamaria De Pellegrin,Gabriele Guardigli,Giovanni Licciardello,Carla Auguadro,Claudio Cuccia,Alessandro Salvioni,Giuseppe Musumeci,Paolo Calabro,Salvatore Novo,Pompilio Faggiano,Nicoletta B. De Cesare,Sergio Berti,Claudio Cavallini,Enrico Puccioni,Marcello Galvani,Maurizio Tespili,Piermarco Piatti,Michela Palvarini,Giuseppe De Luca,Roberto Violini,Alessandro De Leo,Pasquale Perrone Filardi,Maurizio Ferratini,Kazuoki Dai,Haruo Kamiya,Kenji Ando,Yoshihiro Takeda,Yoshihiro Morino,Yoshiki Hata,Kazuo Kimura,Koichi Kishi,Ichiro Michishita,Hiroki Uehara,Toshinori Higashikata,Atsushi Hirayama,Keiji Hirooka,Satoru Sakagami,Shuichi Taguchi,Akihiro Koike,Hiroyuki Fujinaga,Shinji Koba,Ken Kozuma,Tomohiro Kawasaki,Yujiro Ono,Masatoshi Shimizu,Yousuke Katsuda,Atsuyuki Wada,Toshiro Shinke,Junya Ako,Kenshi Fujii,Toshiyuki Takahashi,Tomohiro Sakamoto,Yutaka Furukawa,Hiroshi Sugino,Toshiaki Mano,Noriaki Utsu,Kashima Ito,Takuya Haraguchi,Yasunori Ueda,Akira Nishibe,Kazuteru Fujimoto,Jung Han Yoon,Hun Sik Park,In-Ho Chae,Moo Hyun Kim,Myung Ho Jeong,Seungwoon Rha,Chongjin Kim,Taekjong Hong,Arija Busmane,Natalija Pontaga,Aldis Strelnieks,Iveta Mintale,Iveta Sime,Zaneta Petrulioniene,Roma Kavaliauskiene,Ruta Jurgaitiene,Gintare Sakalyte,Rimvydas Slapikas,Sigute Norkiene,Nerijus Misonis,Aleksandras Kibarskis,Raimondas Kubilius,Stojko Bojovski,Nensi Lozance,Aleksandar Kjovkaroski,Snezana Doncovska,Tiong Kiam Ong,Sazzli Kasim,Oteh Maskon,Balachandran Kandasamy,Houng B. Liew,Wan Mohd Izani Wan Mohamed,Armando Garcia Castillo,Jorge Carrillo Calvillo,Pedro Fajardo Campos,Juan Carlos Nunez Fragoso,Edmundo Alfredo Bayram Llamas,Marco Antonio Alcocer Gamba,Jaime Carranza Madrigal,Luis Gerardo Gonzalez Salas,Enrique Lopez Rosas,Belinda Gonzalez Diaz,Eduardo Salcido Vazquez,Alfredo Nacoud Ackar,Guillermo Antonio Llamas Esperon,Carlos Rodolfo Martinez Sanchez,Maria Guerrero De Leon,Rodrigo Suarez Otero,Guillermo Fanghanel Salmon,Jesus Antonio Perez Rios,Jose Angel Garza Ruiz,Robert W. Breedveld,Pieter A. M. Hoogslag,Harry Suryapranata,Antonius Oomen,Jacobijne J. Wiersma,Ruud M. A. Van Der Wal,Pascalle S. Hooft Van Huysduynen-Monraats,Ioannis Karalis,Gerardus J. E. Verdel,Bart R. G. Brueren,Roland P. Th Troquay,Eric P. Viergever,Nadea Y. Y. Al-Windy,Gerard L. Bartels,Jan H. Cornel,Walter R. M. Hermans,Johannes P. R. Herrman,Robert J. Bos,Reginald G. E. J. Groutars,Coenraad C. Van Der Zwaan,Refik Kaplan,Eelko Ronner,Bjorn E. Groenemeijer,Patrick N. A. Bronzwaer,Anho A. H. Liem,Bernard J. W. M. Rensing,Marcel J. J. A. Bokern,Remco Nijmeijer,Ferry M. R. J. Hersbach,Frank F. Willems,Antonius T. M. Gosselink,John Elliott,Gerard Wilkins,Raewyn Fisher,Douglas Scott,Hamish Hart,Ralph Stewart,Scott Harding,Ian Ternouth,Nicholas Fisher,Denise Aitken,Russell Anscombe,Tadeusz Tomala,Ottar Nygard,Jon Arne Sparby,Kjell Andersen,Lars Gullestad,Jarle Jortveit,Peter S. Munk,Ulf Hurtig,Jorge R. Calderon Ticona,Julio R. Durand Velasquez,Sandra A. Negron Miguel,Enrique S. Sanabria Perez,Jesus M. Carrion Chambilla,Carlos A. Chavez Ayala,Reynaldo P. Castillo Leon,Rolando J. Vargas Gonzales,Jose D. Hernandez Zuniga,Luis A. Camacho Cosavalente,Jorge E. Bravo Mannucci,Nassip C. Llerena Navarro,Yudy M. Roldan Concha,V-ctor E. Rodriguez Chavez,Henry A. Anchante Hernandez,Carlos A. Zea Nunez,Arthur Ferrolino,Rosa Allyn G. Sy,Louie Tirador,Generoso Matiga,Raul Martin Coching,Alisa Bernan,Gregorio Rogelio,Dante D. Morales,Edgar Tan,Adrian Wlodarczak,Krystyna Jaworska,Grzegorz Skonieczny,Lidia Pawlowicz,Pawel Wojewoda,Benita Busz-Papiez,Janusz Bednarski,Aleksander Goch,Pawel Staneta,Elzbieta Dulak,Krzysztof Saminski,Wlodzimierz Krasowski,Wanda Sudnik,Aleksander Zurakowski,Marcin Skorski,Roman Lysek,Beata Miklaszewicz,Jacek Kubica,Jan Andrzej Lipko,Edyta Kostarska-Srokosz,Marek Piepiorka,Anna Drzewiecka,Ryszard Sciborski,Arkadiusz Stasiewski,Tomasz Blicharski,Leszek Bystryk,Michal Szpajer,Marek Korol,Tomasz Czerski,Ewa Mirek-Bryniarska,Jacek Gniot,Andrzej Lubinski,Jerzy Gorny,Edward Franek,Pedro Monteiro,Jose Mesquita Bastos,Helder H. Pereira,Dinis Martins,Filipe Seixo,Carlos Mendonca,Ana Botelho,Bogdan Minescu,Octavian Istratoaie,Dan N. Tesloianu,Gabriel Cristian,Cristian G. C. Podoleanu,Mircea C. A. Constantinescu,Cristina M. Bengus,Constantin Militaru,Doina Rosu,Irinel R. Parepa,Adrian V. Matei,Tom M. Alexandru,Yury Shvarts,Olga Orlikova,Zhanna Kobalava,Olga L. Barbarash,Valentin Markov,Nadezhda Lyamina,Alexander Gordienko,Konstantin Zrazhevsky,Alexander Y. Vishnevsky,Victor Gurevich,Raisa Stryuk,Nikita V. Lomakin,Igor Bokarev,Sergey Shalaev,Larisa Khaisheva,Petr Chizhov,Inna Viktorova,Natalya Osokina,Evgenia Akatova,Galina Chumakova,Igor Libov,Mikhail I. Voevoda,Tatyana V. Tretyakova,Evgeny Baranov,Sergey Shustov,Sergey Yakushin,Ivan Gordeev,Niiaz Khasanov,Olga Reshetko,Tatiana Sotnikova,Olga Molchanova,Konstantin Nikolaev,Liudmila Gapon,Elena Baranova,Zaur Shogenov,Elena Kosmachova,Yuriy Karpov,Anton Povzun,Liudmila Egorova,Vadim V. Tyrenko,Igor G. Ivanov,Dragan Simic,Nikola Ivanovic,Goran Davidovic,Nebojsa Tasic,Milika R. Asanin,Stevo Stojic,Svetlana R. Apostolovic,Stevan Ilic,Biljana Putnikovic,Aleksandar Stankovic,Aleksandra Arandjelovic,Slavica Radovanovic,Jovan Balinovac,Dragan V. Dincic,Petar Seferovic,Slobodan Dodic,Sinisa Dimkovic,Kian-Keong Poh,Hean Yee Ong,Karol Micko,Jan Nociar,Daniel Pella,Peter Fulop,Marian Hranai,Juraj Palka,Juraj Mazur,Ivan Majercak,Andrej Dzupina,Frantisek Fazekas,Jozef Gonsorcik,Viliam Bugan,Juraj Selecky,Gabriel Kamensky,Jaroslava Strbova,Rudolf Smik,Andrej Dukat,Ivan Zuran,Janez Oklukar,Natasa Cernic Suligoj,Matija Cevc,Luka Lipar,Henry P. Cyster,Naresh Ranjith,Clive Corbett,Junaid Bayat,Ellen Makoali Makotoko,Ilse E. Kapp,Matthys M. de V. Basson,Hanlie Lottering,Louis J. Van Zyl,Peter J. Sebastian,Thayabran Pillay,Jan A. Saaiman,Patrick J. Commerford,Soraya Cassimjee,Iftikhar O. Ebrahim,Mahomed Sarvan,Joseph H. Mynhardt,Helmuth Reuter,Rajendran Moodley,Manuel Vida,Angel R. Cequier Fillat,Vicente Bodi Peris,Francisco Fuentes Jimenez,Francisco Marin,Jose M. Cruz Fernandez,Blas Gil-Extremera,Fernando Worner Diz,David Garcia-Dorado,Andres Iniguez,Jose Tunon Fernandez,Jose R. Gonzalez-Juanatey,Javier Fernandez Portales,Fernando Civeira Murillo,Laia Matas Pericas,Jose Luis Zamorano,Manuel De Mora Martin,Jordi Bruguera Cortada,Joaquin J. Alonso Martin,Jose R. De Berrazueta Fernandez,Jose Francisco Diaz Fernandez,Jose Alberto Garcia Lledo,Juan Cosin Sales,Javier Botas Rodriguez,Gabriel Gusi Tragant,Amparo Benedicto,Carlos Gonzalez-Juanatey,Mercedes Camprubi Potau,Ignacio Plaza Perez,Cesar Moris De La Tassa,Pablo Loma-Osorio Rincon,Javier Balaguer Recena,Juan M Escudier,Godwin Constantine,Ruvaiz Haniffa,Nirmali Tissera,Stanley Amarasekera,Nimali Fernando,Jayanthimala Jayawardena,Wijeyasingam Santharaj,Ruvan Ekanayaka,Sepalika Mendis,Vajira Senaratne,Gnanamoorthy Mayurathan,Thilak Sirisena,Ajantha Rajapaksha,Jagath I. Herath,Naomali Amarasena,Stefan Berglund,Gundars Rasmanis,Nils Witt,Georgios Mourtzinis,Peter Nicol,Ole Hansen,Stefano Romeo,Steen Agergaard Jensen,Ingemar Torstensson,Ulf Ahremark,Torbjorn Sundelin,Tiziano Moccetti,Christian Mueller,Francois Mach,Ronald Binder,Wei-Chuan Tsai,Kwo-Chang Ueng,Wen-Ter Lai,Ming-En Liu,Juey-Jen Hwang,Wei-Hsian Yin,I-Chang Hsieh,Wei Hsiang Lin,Jen-Yuan Kuo,Tsuei-Yuan Huang,Chih-Yuan Fang,Pinij Kaewsuwanna,Wasant Soonfuang,Woravut Jintapakorn,Apichard Sukonthasarn,Nattawut Wongpraparut,Krisada Sastravaha,Nakarin Sansanayudh,Wirash Kehasukcharoen,Dilok Piyayotai,Ahmet Camsari,Hakan Kultursay,Bulent Mutlu,Murat Ersanli,Mustafa Demirtas,Cevat Kirma,Ertan Ural,Lale Koldas,Oleksandr Karpenko,Alexander Prokhorov,Ihor Vakaluyk,Halyna Myshanych,Dmytro Reshotko,Valeriy Batushkin,Leonid Rudenko,Ihor Kovalskyi,Mykola Kushnir,Vira Tseluyko,Yuriy Mostovoy,Mykola Stanislavchuk,Yulian Kyiak,Yuriy Karpenko,Yaroslav Malynovsky,Andriy Klantsa,Oles Kutniy,Ekaterina Amosova,Viktor Tashchuk,Oleh Leshchuk,Mykola Rishko,Mykola Kopytsya,Andriy Yagensky,Mykola Vatutin,Andriy Bagriy,Olga M. Barna,Olexiy Ushakov,Georgiy Dzyak,Borys Goloborodko,Anatolii Rudenko,Jasper Trevelyan,Azfar Zaman,Kaeng Lee,Andrew Moriarty,Rajesh K. Aggarwal,Piers Clifford,Yuk-Ki Wong,Syed M. R. Iqbal,Eduardas Subkovas,Denise Braganza,David Sarkar,Robert Storey,Huw Griffiths,Sam Mcclure,Rangasamy Muthusamy,John Kurian,Terry Levy,Craig Barr,Honer Kadr,Robert Gerber,Audrius Simaitis,Handrean Soran,Anthony Mathur,Adrian Brodison,Richard Oliver,Telal Mudawi,Timothy Reynolds,David Sharman,Rob Butler,Peter Wilkinson,Gregory Y. H. Lip,Julian Halcox,Gil Vardi,Duccio Baldari,David Brabham,Charles Treasure,Charles Dahl,Bruce Palmer,Alan Wiseman,Abul Khan,Sanjeev Puri,Ann Elizabeth Mohart,Carlos Ince,Enrique Flores,Scott Wright,Shi-Chi Cheng,Michael Rosenberg,William Rogers,Edward Kosinski,Les Forgosh,Jonathan Waltman,Misal Khan,Mohammad Shoukfeh,Georges Dagher,Ira Lieber,Priya Kumar,Cara East,Perry Krichmar,Lindsey White,Thomas Knickelbine,Thomas Haldis,Eve Gillespie,David Suh,Imran Arif,Faiq Akhter,Eric Carlson,Michael D'Urso,Fadi El-Ahdab,William Nelson,Barry Harris,Steven Cohen,Luther Carter,Kenneth Sabatino,Tariq Haddad,Amir Malik,Sunder Rao,Angel Mulkay,Ion Jovin,Kim Klancke,Vinay Malhotra,Sai K. Devarapalli,Michael Koren,Harish Chandna,George Dodds,Matthew Janik,Joseph Moran,Andrew Sumner,John Kobayashi,William Davis,Shahram Yazdani,John Pasquini,Maitreya Thakkar,Amarnath Vedere,Wayne Leimbach,James Rider,Narendra Singh,Anil V. Shah,Denise Janosik,Carl Pepine,Brett Berman,Joseph Gelormini,Christopher Daniels,Friederike Keating,Nicholas I. Kondo,Sanjay Shetty,Winfried Waider,Theodore Takata,Mazen Abu-Fadel,Vipul Shah,Rahul Aggarwal,Mark Izzo,Anil Kumar,Brack Hattler,Chad Link,Anna Bortnick,George Kinzfogl,Arnold Ghitis,John Larry,Edward Teufel,Peter Kuhlman,Brent Mclaurin,Wenwu Zhang,Stephen Thew,Jalal Abbas,Matthew White,Nandkishore Ranadive,Christian Gring,David Henderson,Timothy Schuchard,Naim Farhat,Geoffrey Kline,Sharan Mahal,Jack Whitaker,Shawn Speirs,Rolf Andersen,Nizar Daboul,Phillip Horwitz,Zubair Jafar,Joseph Mcgarvey,Vipul Panchal,Stephen Voyce,Thomas Blok,William Sheldon,Masoud M. Azizad,Carsten Schmalfuss,Mark Picone,William Herzog,Jason Lindsey,Rosemary Nowins,Norman Lepor,Mahfouz El Shahawy,Howard Weintraub,Anand Irimpen,Wade May,Thomas Galski,Alan Chu,Freny Mody,Zachary Hodes,James Fairlamb,Charles Lambert,Ajit Raisinghani,Antonio Abbate,Marilyn King,Charles Carey,Jaime Gerber,Liwa Younis,Hyeun (Tom) Park,Mladen Vidovich,Thomas Knutson,Dennis Friedman,Fred Chaleff,Arthur Loussararian,Carey Kimmelstiel,Kevin Silver,Malcolm Foster,Glen Tonnessen,Mohamadali Amlani,Andreas Wali,Christopher Malozzi,Keattiyoat Wattanakit,Philip J. O'Donnell,Dinesh Singal,Naseem Jaffrani,Sridhar Banuru,Daniel Fisher,Mark Xenakis,Neal Perlmutter,Ravi Bhagwat,James Strader,Ayim Akyea-Djamson,Ajay Labroo,Kwan Lee,H. John Marais,Edmund Claxton,Martin Berk,Peter Rossi,Parag Joshi,Ajit S. Khaira,Greg Kumkumian,Steven Lupovitch,Joshua Purow,Stephen Welka,David Hoffman,Stuart Fischer,Eugene Soroka,Donald Eagerton,Samir Pancholy,Michael Ray,Michael Farrar,Stewart Pollock,William J. French,Steve Diamantis,Lawrence Gimple,Steven Schwartz,Edward Pereira,Douglas Spriggs,Janet Strain,Anthony Vo,Majed Chane,Jason Hall,Nampalli Vijay,Kapildeo Lotun,F. Martin Lester,Ahed Nahhas,Theodore Pope,Paul Nager,Rakesh Vohra,Riyaz Bashir,Hinan Ahmed,Michael Berlowitz,Robert Fishberg,Robert Barrucco,Eric Yang,Michael Radin,Daniel Sporn,Steven Eisenberg,Joel Landzberg,Martin Mcgough,Samir Turk,Michael Schwartz,P. Sandy Sundram,Diwakar Jain,Mark Zainea,Carlos Bayron,Ronald Karlsberg,Henry Lui,William Keen,Donald Westerhausen,Sandeep Khurana,Himanshu Agarwal,Jessica Birchem,William Penny,Mark Chang,John M. Gilbert,Gopal Chalavarya,Charles Eaton,John F. Schmedtje,Stuart Christenson,Douglas Denham,Alexander Macdonell,Paul Gibson,Aref Rahman,Tammam Al Joundi,Gary Conrad,Purushotham Kotha,Michael Love,Gregory Giesler,Howard Rubenstein,Laura Akright,Branislav Schifferdecker,Justine Krawczyk,Terry Wells,James Welker,Robert Foster,Richard Gilmore,Jay Anderson,Douglas Jacoby,Bill Harris,Geraldine Gardner,Ramprasad Dandillaya,Kishor Vora,John Kostis,John Hunter,David Laxson,Eric Ball

Contents Vol. 33,2012

A Cross‐sectional Descriptive Analysis of Authorship Trends in China‐based Dermatology Literature in International Journals, 2000–2010

Contents Vol. 45, 2011

Contents Vol. 5, 2019

Contents Vol. 4, 2016

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

HBPD: Table of Contents Vol. 7, No. 4, 2008

Other articles (title, authors and affiliations only)

Vol. 116, February 2018

Expert Consensus on Perioperative Management of Liver Transplantation in Adults with Acute-on-chronic Liver Failure

The Study Design and Methodology of Antibiotic Duration in Hematological Patients with Pseudomonas Aeruginosa Bloodstream Infection.

SUBJECT INDEX TO VOLUME 7 (2020)

Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Diseases

The Necessity of Studying Antibiotic Duration in Acute Leukemia Patients with Pseudomonas Aeruginosa Bloodstream Infection: A Response to Terada and Kanno

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome.

Withdrawal: Prospective Randomized Comparison Between Upgraded “2C3L” Versus PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT‐AF Trial Design

Chemical Constituents of Plants from the Genus Geum

Sex-specific Characteristics and Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.

Cmar_a_307079 6823..6832

Severe Septic Shock after Colonoscopic Polypectomy